EntityQ411175· pop 10· linked from 51 articles

mifamurtide

Mifamurtide (trade name Mepact, marketed by Takeda) is a drug against osteosarcoma, a kind of bone cancer mainly affecting children and young adults, which is lethal in over half of cases. The drug was approved in Europe in March 2009.

Key facts

Drug.legal_status: Rx
Drug.Verifiedfields: changed
Drug.Watchedfields: changed
Drug.verifiedrevid: 407798436
Drug.IUPAC_name: 2-[(N-{(2R)-[(2-acetamido-2,3-dideoxy-D-glucopyranos-3-yl)oxy]-propanoyl}-L-alanyl-D-isoglutaminyl-L-alanyl)amino]ethyl (2R)-2,3-bis(hexadecanoyloxy)propyl hydrogen phosphate
Drug.image: Mifamurtide.svg
Drug.image_class: skin-invert-image
Drug.width: 300
Drug.tradename: Mepact
Drug.licence_EU: yes
Drug.pregnancy_category: not investigated
Drug.routes_of_administration: intravenous liposomal infusion over one hour
Drug.bioavailability: N/A
Drug.elimination_half life: minutes (in plasma)18 hrs (terminal)
Drug.CAS_number: 83461-56-7
Drug.CAS_supplemental: (mifamurtide sodium)
Drug.ATC_prefix: L03
Drug.ATC_suffix: AX15

via Wikipedia infobox

Article

10 sections

Contents

Medical uses
Adverse effects
Interactions
Pharmacology
Mechanism of action
Pharmacokinetics
Chemistry
Synthesis
History
References

{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 407798436 | IUPAC_name = 2-[(N-{(2R)-[(2-acetamido-2,3-dideoxy-D-glucopyranos-3-yl)oxy]-propanoyl}-L-alanyl-D-isoglutaminyl-L-alanyl)amino]ethyl (2R)-2,3-bis(hexadecanoyloxy)propyl hydrogen phosphate | image = Mifamurtide.svg | image_class = skin-invert-image | width = 300